Dexamethasone and Multihance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dexamethasone (dexamethasone) and Multihance (gadobenate dimeglumine). Common drug interactions include skin fibrosis among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Dexamethasone and Multihance. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Dexamethasone?

Dexamethasone has active ingredients of dexamethasone. It is often used in multiple myeloma. eHealthMe is studying from 161,927 Dexamethasone users. Check the latest studies of Dexamethasone.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

On Jul, 31, 2026

37 people who take Dexamethasone and Multihance together, and have interactions are studied.

Dexamethasone and Multihance drug interactions.

What are the common drug interactions of Dexamethasone and Multihance, by gender? *:

female:

Skin fibrosis (fibrous tissue formation on skin)
Skin hyperpigmentation (disorders affect the colour of your skin)
Skin lesion
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema peripheral (superficial swelling)
Pain
Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Skin tightness
Dry skin

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Mobility decreased (ability to move is reduced)
Major depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings)
Rash
Renal disorder (kidney disease)
Skin disorder (skin disease)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Interstitial lung disease
Joint contracture (a permanent shortening of a muscle or joint)
Metaplasia (change in the type of adult cells in a tissue to a form abnormal for that tissue)

What are the common drug interactions of Dexamethasone and Multihance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Muscle contracture (a permanent shortening of a muscle)
Skin fibrosis (fibrous tissue formation on skin)
Discomfort
Pain
Cardiac valve disease (heart valve disease)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Nephrogenic fibrosing dermopathy (involves fibrosis of skin, joints, eyes due to kidney disease)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Cardiac arrest
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)

20-29:

n/a

30-39:

n/a

40-49:

Arthralgia (joint pain)
Asthenia (weakness)
Chronic kidney disease
Deformity (disfigurement)
Erythema (redness of the skin)
Exfoliative rash (scaly red generalized skin rash)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Gait disturbance
General physical health deterioration (weak health status)
Joint contracture (a permanent shortening of a muscle or joint)

50-59:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Dry skin
Erythema (redness of the skin)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Hyperkeratosis (thickening of the outer layer of the skin)
Impaired healing
Mobility decreased (ability to move is reduced)
Muscular weakness (muscle weakness)
Oedema (fluid collection in tissue)

60+:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema peripheral (superficial swelling)
Skin induration (an abnormally hard spot or area on the skin)
Skin plaque (red, scaly patches to appear on the skin)
Interstitial lung disease
Sinus tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node)
Injection site bruising
Injection site erythema (redness at injection site)
Injection site pain
Injection site pruritus (severe itching at injection site)

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 13 people, 35.14%
Joint Pain: 9 people, 24.32%
Nuclear Magnetic Resonance Imaging Abdominal: 8 people, 21.62%
Catheter Related Complication: 8 people, 21.62%
Weakness: 7 people, 18.92%
Dizziness: 7 people, 18.92%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 6 people, 16.22%
Anaemia (lack of blood): 5 people, 13.51%
Renal Osteodystrophy (a bone disease occurs when the kidneys fail to maintain the proper levels of calcium and phosphorus in the blood): 3 people, 8.11%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 3 people, 8.11%

* Approximation only. Some reports may have incomplete information.

Do you take Dexamethasone and Multihance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously